The announcement details the initiation of a Phase II clinical trial for SYS6041, a drug developed by the subsidiary Giant Biologics, to treat recurrent ovarian cancer. The trial, approved by the NMPA, aims to evaluate the safety and efficacy of SYS6041 in combination therapy. Patient recruitment is underway, and the company acknowledges the inherent risks in drug development.
Summary generated by AI · Always verify with source document
Stock Code: 300765
Stock Abbreviation: CSPC Pharmaceutical Group
Announcement No.: 2026-069
CSPC Pharmaceutical Group Limited
Announcement on the Initiation of Phase II Clinical Trial of SYS6041 by Subsidiary
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.